AstraZeneca Enters Agreement to Lower U.S. Drug Prices

AstraZeneca has entered an agreement with President Donald J. Trump’s administration to lower the cost of prescription medicines for Americans while investing in America’s biopharmaceutical innovation.

AstraZeneca CEO Pascal Soriot joined President Trump and members of his Administration to confirm the company voluntarily met all requests set out in the President’s July 31^st letter. The Company agrees to a range of measures which will enable Americans to access medicines at prices that are equalized with those available in wealthy countries. Specific terms of the agreement were not disclosed.

As part of the agreement, AstraZeneca will provide Direct-to-Consumer (DTC) sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80%. AstraZeneca will participate in the TrumpRx.gov direct purchasing platform, which will allow patients to purchase medicines at a reduced cash price from AstraZeneca.

AstraZeneca has also reached an agreement with the U.S. Department of Commerce to delay Section 232 tariffs for three years, enabling the company to fully onshore drug manufacturing so that all of its medicines sold in America are made in America. 

Investment in U.S. R&D, Manufacturing

The Company recently announced $50 billion investment in U.S. manufacturing and R&D over the next five years.

AstraZeneca recently broke ground in Virginia for a facility that will support its weight management and metabolic portfolio and antibody drug conjugate cancer pipeline, representing the company’s largest single investment in a manufacturing facility to date.

Additionally, a newly expanded manufacturing facility in Coppell, TX, will open next week. The company will also open a cell therapy manufacturing facility in Rockville, MD early next year and its second major R&D center in Cambridge, MA will open in late 2026.

This is the second agreement with a major pharmaceutical company to lower drug prices in the U.S.

Pfizer Reaches Agreement with U.S. Government to Lower Drug Costs